Cellect Announces Successful First Cancer Patient Stem Cell Transplant
Mar 27, 2017 11:03 am UTC| Business
Cellect’s technology, ApoGraft™, aims to become a game changerin stem cells transplantations for cancer treatments Company gets green light from DSMB Board for enrolling additional 2 cancer patients for ApoGraft™...
Mar 27, 2017 11:02 am UTC| Business
Metso Corporation, Stock exchange release, March 27, 2017 at 2:00 p.m. EEST Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.'s holding in Metso Metso Corporation has...
BroadSoft Hub Now Commercially Available For AI-Powered Workforce Communications
Mar 27, 2017 11:02 am UTC| Business
GAITHERSBURG, Md., March 27, 2017 -- BroadSoft, Inc. (NASDAQ:BSFT), a global unified communication software as a service (UCaaS) leader, today announced the commercial availability of Hub, a BroadSoft Business cloud...
ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
Mar 27, 2017 11:02 am UTC| Business
LEIDEN, the Netherlands, March 27, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it appointed David M. Rodman, MD as Chief Development Strategy Officer. Dr. Rodman has had a long career in drug...
Mar 27, 2017 11:02 am UTC| Business
PHOENIX, March 27, 2017 -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that, effective April 17, 2017, Saeed Motahari, will become the Company’s President and Chief Executive...
Bazaarvoice and TurnTo Form Partnership to Bring More Consumer-Generated Content to Retailers
Mar 27, 2017 11:02 am UTC| Business
AUSTIN, Texas and NEW YORK, March 27, 2017 -- Bazaarvoice, Inc. (Nasdaq:BV) and TurnTo Networks announced today they have reached an agreement to offer TurnTo’s brand clients the opportunity to syndicate their ratings...
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2016 Financial Results
Mar 27, 2017 11:02 am UTC| Business
NEWTOWN, Pa., March 27, 2017 -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a...